 | • レポートコード：MRC2312MG03304 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥468,000 (USD3,250) | ▷ お問い合わせ |
| Multi User | ￥608,400 (USD4,225) | ▷ お問い合わせ |
| Enterprise User | ￥702,000 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Global High-end Generic Drug Market 調査レポートは次の情報を含め、グローバルにおけるのハイエンド・ジェネリック医薬品市場規模と予測を収録しています。 ・世界のハイエンド・ジェネリック医薬品市場：売上、2018年-2023年、2024年-2029年 ・世界のハイエンド・ジェネリック医薬品市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のハイエンド・ジェネリック医薬品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「処方薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。 ハイエンド・ジェネリック医薬品のグローバル主要企業は、Viatris、 Teva、 Organon、 Sun Pharma、 Bausch Health、 Mylan NV、 Novartis AG、 Pfizer Inc、 Fresenius SE & Co、 Lupin Limited、 Endo Pharmaceuticals Inc、 Aurobindo Pharma Limited、 Warner (India) Pharma Private Limited、 Shijiazhuang Pharma Group、 Fosun Pharma、 Yangtze River Pharmaceutical Group、 Sichuan KELUN PHARMACEUTICAL Co., Ltd.、 Nantong Beite Pharmaceutical Machinery Co.,Ltd、 CR Pharmaceutical Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル社は、ハイエンド・ジェネリック医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別マーケット分析】 世界のハイエンド・ジェネリック医薬品市場：タイプ別、2018年-2023年、2024年-2029年 世界のハイエンド・ジェネリック医薬品市場：タイプ別市場シェア、2022年 ・処方薬、非処方薬 世界のハイエンド・ジェネリック医薬品市場：用途別、2018年-2023年、2024年-2029年 世界のハイエンド・ジェネリック医薬品市場：用途別市場シェア、2022年 ・病院、薬局、その他 世界のハイエンド・ジェネリック医薬品市場：地域・国別、2018年-2023年、2024年-2029年 世界のハイエンド・ジェネリック医薬品市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競争分析】 また、当レポートは主要な参入企業の分析を提供します。 ・主要企業におけるハイエンド・ジェネリック医薬品のグローバル売上、2018年-2023年 ・主要企業におけるハイエンド・ジェネリック医薬品のグローバル売上シェア、2022年 ・主要企業におけるハイエンド・ジェネリック医薬品のグローバル販売量、2018年-2023年 ・主要企業におけるハイエンド・ジェネリック医薬品のグローバル販売量シェア、2022年 さらに、当レポートは主要企業の情報を提示します。 Viatris、 Teva、 Organon、 Sun Pharma、 Bausch Health、 Mylan NV、 Novartis AG、 Pfizer Inc、 Fresenius SE & Co、 Lupin Limited、 Endo Pharmaceuticals Inc、 Aurobindo Pharma Limited、 Warner (India) Pharma Private Limited、 Shijiazhuang Pharma Group、 Fosun Pharma、 Yangtze River Pharmaceutical Group、 Sichuan KELUN PHARMACEUTICAL Co., Ltd.、 Nantong Beite Pharmaceutical Machinery Co.,Ltd、 CR Pharmaceutical Group ************************************************************* ・調査・分析レポートの概要 ハイエンド・ジェネリック医薬品市場の定義 市場セグメント 世界のハイエンド・ジェネリック医薬品市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のハイエンド・ジェネリック医薬品市場規模 世界のハイエンド・ジェネリック医薬品市場規模：2022年 VS 2029年 世界のハイエンド・ジェネリック医薬品市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのハイエンド・ジェネリック医薬品の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のハイエンド・ジェネリック医薬品製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：処方薬、非処方薬 ハイエンド・ジェネリック医薬品のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、薬局、その他 ハイエンド・ジェネリック医薬品の用途別グローバル売上・予測 ・地域別市場分析 地域別ハイエンド・ジェネリック医薬品市場規模 2022年と2029年 地域別ハイエンド・ジェネリック医薬品売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど） Viatris、 Teva、 Organon、 Sun Pharma、 Bausch Health、 Mylan NV、 Novartis AG、 Pfizer Inc、 Fresenius SE & Co、 Lupin Limited、 Endo Pharmaceuticals Inc、 Aurobindo Pharma Limited、 Warner (India) Pharma Private Limited、 Shijiazhuang Pharma Group、 Fosun Pharma、 Yangtze River Pharmaceutical Group、 Sichuan KELUN PHARMACEUTICAL Co., Ltd.、 Nantong Beite Pharmaceutical Machinery Co.,Ltd、 CR Pharmaceutical Group ... |
This research report provides a comprehensive analysis of the High-end Generic Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global High-end Generic Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of High-end Generic Drug, challenges faced by the industry, and potential opportunities for market players.
The global High-end Generic Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The High-end Generic Drug market presents opportunities for various stakeholders, including Hospital, Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in High-end Generic Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global High-end Generic Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
As people’s demand for medical care increases, pharmaceutical technology advances and the prevalence of chronic diseases increases, and pharmaceutical R&D activities and investments increase, the high-end generic drug industry is developing well. However, the industry also faces various challenges, such as strict market supervision, high research and development costs, expiration of drug patents, and declining revenue. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for high-end generic pharmaceutical companies to be nimble in responding to emerging public health needs.
Key Features:
The research report on the High-end Generic Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the High-end Generic Drug market.
Market Overview: The report provides a comprehensive overview of the High-end Generic Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Prescription Drugs, Non-prescription Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the High-end Generic Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the High-end Generic Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the High-end Generic Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the High-end Generic Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the High-end Generic Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the High-end Generic Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for High-end Generic Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the High-end Generic Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
High-end Generic Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Prescription Drugs
Non-prescription Drugs
Market segment by Application
Hospital
Pharmacy
Others
Global High-end Generic Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Viatris
Teva
Organon
Sun Pharma
Bausch Health
Mylan NV
Novartis AG
Pfizer Inc
Fresenius SE & Co
Lupin Limited
Endo Pharmaceuticals Inc
Aurobindo Pharma Limited
Warner (India) Pharma Private Limited
Shijiazhuang Pharma Group
Fosun Pharma
Yangtze River Pharmaceutical Group
Sichuan KELUN PHARMACEUTICAL Co., Ltd.
Nantong Beite Pharmaceutical Machinery Co.,Ltd
CR Pharmaceutical Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of High-end Generic Drug, market overview.
Chapter 2: Global High-end Generic Drug market size in revenue.
Chapter 3: Detailed analysis of High-end Generic Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of High-end Generic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 High-end Generic Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global High-end Generic Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global High-end Generic Drug Overall Market Size
2.1 Global High-end Generic Drug Market Size: 2022 VS 2029
2.2 Global High-end Generic Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top High-end Generic Drug Players in Global Market
3.2 Top Global High-end Generic Drug Companies Ranked by Revenue
3.3 Global High-end Generic Drug Revenue by Companies
3.4 Top 3 and Top 5 High-end Generic Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies High-end Generic Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 High-end Generic Drug Players in Global Market
3.6.1 List of Global Tier 1 High-end Generic Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 High-end Generic Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global High-end Generic Drug Market Size Markets, 2022 & 2029
4.1.2 Prescription Drugs
4.1.3 Non-prescription Drugs
4.2 By Type – Global High-end Generic Drug Revenue & Forecasts
4.2.1 By Type – Global High-end Generic Drug Revenue, 2018-2023
4.2.2 By Type – Global High-end Generic Drug Revenue, 2024-2029
4.2.3 By Type – Global High-end Generic Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global High-end Generic Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Others
5.2 By Application – Global High-end Generic Drug Revenue & Forecasts
5.2.1 By Application – Global High-end Generic Drug Revenue, 2018-2023
5.2.2 By Application – Global High-end Generic Drug Revenue, 2024-2029
5.2.3 By Application – Global High-end Generic Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global High-end Generic Drug Market Size, 2022 & 2029
6.2 By Region – Global High-end Generic Drug Revenue & Forecasts
6.2.1 By Region – Global High-end Generic Drug Revenue, 2018-2023
6.2.2 By Region – Global High-end Generic Drug Revenue, 2024-2029
6.2.3 By Region – Global High-end Generic Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America High-end Generic Drug Revenue, 2018-2029
6.3.2 US High-end Generic Drug Market Size, 2018-2029
6.3.3 Canada High-end Generic Drug Market Size, 2018-2029
6.3.4 Mexico High-end Generic Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe High-end Generic Drug Revenue, 2018-2029
6.4.2 Germany High-end Generic Drug Market Size, 2018-2029
6.4.3 France High-end Generic Drug Market Size, 2018-2029
6.4.4 U.K. High-end Generic Drug Market Size, 2018-2029
6.4.5 Italy High-end Generic Drug Market Size, 2018-2029
6.4.6 Russia High-end Generic Drug Market Size, 2018-2029
6.4.7 Nordic Countries High-end Generic Drug Market Size, 2018-2029
6.4.8 Benelux High-end Generic Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia High-end Generic Drug Revenue, 2018-2029
6.5.2 China High-end Generic Drug Market Size, 2018-2029
6.5.3 Japan High-end Generic Drug Market Size, 2018-2029
6.5.4 South Korea High-end Generic Drug Market Size, 2018-2029
6.5.5 Southeast Asia High-end Generic Drug Market Size, 2018-2029
6.5.6 India High-end Generic Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America High-end Generic Drug Revenue, 2018-2029
6.6.2 Brazil High-end Generic Drug Market Size, 2018-2029
6.6.3 Argentina High-end Generic Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa High-end Generic Drug Revenue, 2018-2029
6.7.2 Turkey High-end Generic Drug Market Size, 2018-2029
6.7.3 Israel High-end Generic Drug Market Size, 2018-2029
6.7.4 Saudi Arabia High-end Generic Drug Market Size, 2018-2029
6.7.5 UAE High-end Generic Drug Market Size, 2018-2029
7 High-end Generic Drug Companies Profiles
7.1 Viatris
7.1.1 Viatris Company Summary
7.1.2 Viatris Business Overview
7.1.3 Viatris High-end Generic Drug Major Product Offerings
7.1.4 Viatris High-end Generic Drug Revenue in Global Market (2018-2023)
7.1.5 Viatris Key News & Latest Developments
7.2 Teva
7.2.1 Teva Company Summary
7.2.2 Teva Business Overview
7.2.3 Teva High-end Generic Drug Major Product Offerings
7.2.4 Teva High-end Generic Drug Revenue in Global Market (2018-2023)
7.2.5 Teva Key News & Latest Developments
7.3 Organon
7.3.1 Organon Company Summary
7.3.2 Organon Business Overview
7.3.3 Organon High-end Generic Drug Major Product Offerings
7.3.4 Organon High-end Generic Drug Revenue in Global Market (2018-2023)
7.3.5 Organon Key News & Latest Developments
7.4 Sun Pharma
7.4.1 Sun Pharma Company Summary
7.4.2 Sun Pharma Business Overview
7.4.3 Sun Pharma High-end Generic Drug Major Product Offerings
7.4.4 Sun Pharma High-end Generic Drug Revenue in Global Market (2018-2023)
7.4.5 Sun Pharma Key News & Latest Developments
7.5 Bausch Health
7.5.1 Bausch Health Company Summary
7.5.2 Bausch Health Business Overview
7.5.3 Bausch Health High-end Generic Drug Major Product Offerings
7.5.4 Bausch Health High-end Generic Drug Revenue in Global Market (2018-2023)
7.5.5 Bausch Health Key News & Latest Developments
7.6 Mylan NV
7.6.1 Mylan NV Company Summary
7.6.2 Mylan NV Business Overview
7.6.3 Mylan NV High-end Generic Drug Major Product Offerings
7.6.4 Mylan NV High-end Generic Drug Revenue in Global Market (2018-2023)
7.6.5 Mylan NV Key News & Latest Developments
7.7 Novartis AG
7.7.1 Novartis AG Company Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG High-end Generic Drug Major Product Offerings
7.7.4 Novartis AG High-end Generic Drug Revenue in Global Market (2018-2023)
7.7.5 Novartis AG Key News & Latest Developments
7.8 Pfizer Inc
7.8.1 Pfizer Inc Company Summary
7.8.2 Pfizer Inc Business Overview
7.8.3 Pfizer Inc High-end Generic Drug Major Product Offerings
7.8.4 Pfizer Inc High-end Generic Drug Revenue in Global Market (2018-2023)
7.8.5 Pfizer Inc Key News & Latest Developments
7.9 Fresenius SE & Co
7.9.1 Fresenius SE & Co Company Summary
7.9.2 Fresenius SE & Co Business Overview
7.9.3 Fresenius SE & Co High-end Generic Drug Major Product Offerings
7.9.4 Fresenius SE & Co High-end Generic Drug Revenue in Global Market (2018-2023)
7.9.5 Fresenius SE & Co Key News & Latest Developments
7.10 Lupin Limited
7.10.1 Lupin Limited Company Summary
7.10.2 Lupin Limited Business Overview
7.10.3 Lupin Limited High-end Generic Drug Major Product Offerings
7.10.4 Lupin Limited High-end Generic Drug Revenue in Global Market (2018-2023)
7.10.5 Lupin Limited Key News & Latest Developments
7.11 Endo Pharmaceuticals Inc
7.11.1 Endo Pharmaceuticals Inc Company Summary
7.11.2 Endo Pharmaceuticals Inc Business Overview
7.11.3 Endo Pharmaceuticals Inc High-end Generic Drug Major Product Offerings
7.11.4 Endo Pharmaceuticals Inc High-end Generic Drug Revenue in Global Market (2018-2023)
7.11.5 Endo Pharmaceuticals Inc Key News & Latest Developments
7.12 Aurobindo Pharma Limited
7.12.1 Aurobindo Pharma Limited Company Summary
7.12.2 Aurobindo Pharma Limited Business Overview
7.12.3 Aurobindo Pharma Limited High-end Generic Drug Major Product Offerings
7.12.4 Aurobindo Pharma Limited High-end Generic Drug Revenue in Global Market (2018-2023)
7.12.5 Aurobindo Pharma Limited Key News & Latest Developments
7.13 Warner (India) Pharma Private Limited
7.13.1 Warner (India) Pharma Private Limited Company Summary
7.13.2 Warner (India) Pharma Private Limited Business Overview
7.13.3 Warner (India) Pharma Private Limited High-end Generic Drug Major Product Offerings
7.13.4 Warner (India) Pharma Private Limited High-end Generic Drug Revenue in Global Market (2018-2023)
7.13.5 Warner (India) Pharma Private Limited Key News & Latest Developments
7.14 Shijiazhuang Pharma Group
7.14.1 Shijiazhuang Pharma Group Company Summary
7.14.2 Shijiazhuang Pharma Group Business Overview
7.14.3 Shijiazhuang Pharma Group High-end Generic Drug Major Product Offerings
7.14.4 Shijiazhuang Pharma Group High-end Generic Drug Revenue in Global Market (2018-2023)
7.14.5 Shijiazhuang Pharma Group Key News & Latest Developments
7.15 Fosun Pharma
7.15.1 Fosun Pharma Company Summary
7.15.2 Fosun Pharma Business Overview
7.15.3 Fosun Pharma High-end Generic Drug Major Product Offerings
7.15.4 Fosun Pharma High-end Generic Drug Revenue in Global Market (2018-2023)
7.15.5 Fosun Pharma Key News & Latest Developments
7.16 Yangtze River Pharmaceutical Group
7.16.1 Yangtze River Pharmaceutical Group Company Summary
7.16.2 Yangtze River Pharmaceutical Group Business Overview
7.16.3 Yangtze River Pharmaceutical Group High-end Generic Drug Major Product Offerings
7.16.4 Yangtze River Pharmaceutical Group High-end Generic Drug Revenue in Global Market (2018-2023)
7.16.5 Yangtze River Pharmaceutical Group Key News & Latest Developments
7.17 Sichuan KELUN PHARMACEUTICAL Co., Ltd.
7.17.1 Sichuan KELUN PHARMACEUTICAL Co., Ltd. Company Summary
7.17.2 Sichuan KELUN PHARMACEUTICAL Co., Ltd. Business Overview
7.17.3 Sichuan KELUN PHARMACEUTICAL Co., Ltd. High-end Generic Drug Major Product Offerings
7.17.4 Sichuan KELUN PHARMACEUTICAL Co., Ltd. High-end Generic Drug Revenue in Global Market (2018-2023)
7.17.5 Sichuan KELUN PHARMACEUTICAL Co., Ltd. Key News & Latest Developments
7.18 Nantong Beite Pharmaceutical Machinery Co.,Ltd
7.18.1 Nantong Beite Pharmaceutical Machinery Co.,Ltd Company Summary
7.18.2 Nantong Beite Pharmaceutical Machinery Co.,Ltd Business Overview
7.18.3 Nantong Beite Pharmaceutical Machinery Co.,Ltd High-end Generic Drug Major Product Offerings
7.18.4 Nantong Beite Pharmaceutical Machinery Co.,Ltd High-end Generic Drug Revenue in Global Market (2018-2023)
7.18.5 Nantong Beite Pharmaceutical Machinery Co.,Ltd Key News & Latest Developments
7.19 CR Pharmaceutical Group
7.19.1 CR Pharmaceutical Group Company Summary
7.19.2 CR Pharmaceutical Group Business Overview
7.19.3 CR Pharmaceutical Group High-end Generic Drug Major Product Offerings
7.19.4 CR Pharmaceutical Group High-end Generic Drug Revenue in Global Market (2018-2023)
7.19.5 CR Pharmaceutical Group Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. High-end Generic Drug Market Opportunities & Trends in Global Market
Table 2. High-end Generic Drug Market Drivers in Global Market
Table 3. High-end Generic Drug Market Restraints in Global Market
Table 4. Key Players of High-end Generic Drug in Global Market
Table 5. Top High-end Generic Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global High-end Generic Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global High-end Generic Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies High-end Generic Drug Product Type
Table 9. List of Global Tier 1 High-end Generic Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 High-end Generic Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global High-end Generic Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - High-end Generic Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - High-end Generic Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global High-end Generic Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - High-end Generic Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - High-end Generic Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global High-end Generic Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global High-end Generic Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global High-end Generic Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America High-end Generic Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America High-end Generic Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe High-end Generic Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe High-end Generic Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia High-end Generic Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia High-end Generic Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America High-end Generic Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America High-end Generic Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa High-end Generic Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa High-end Generic Drug Revenue, (US$, Mn), 2024-2029
Table 30. Viatris Company Summary
Table 31. Viatris High-end Generic Drug Product Offerings
Table 32. Viatris High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Viatris Key News & Latest Developments
Table 34. Teva Company Summary
Table 35. Teva High-end Generic Drug Product Offerings
Table 36. Teva High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Teva Key News & Latest Developments
Table 38. Organon Company Summary
Table 39. Organon High-end Generic Drug Product Offerings
Table 40. Organon High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Organon Key News & Latest Developments
Table 42. Sun Pharma Company Summary
Table 43. Sun Pharma High-end Generic Drug Product Offerings
Table 44. Sun Pharma High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Sun Pharma Key News & Latest Developments
Table 46. Bausch Health Company Summary
Table 47. Bausch Health High-end Generic Drug Product Offerings
Table 48. Bausch Health High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Bausch Health Key News & Latest Developments
Table 50. Mylan NV Company Summary
Table 51. Mylan NV High-end Generic Drug Product Offerings
Table 52. Mylan NV High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Mylan NV Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG High-end Generic Drug Product Offerings
Table 56. Novartis AG High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis AG Key News & Latest Developments
Table 58. Pfizer Inc Company Summary
Table 59. Pfizer Inc High-end Generic Drug Product Offerings
Table 60. Pfizer Inc High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Pfizer Inc Key News & Latest Developments
Table 62. Fresenius SE & Co Company Summary
Table 63. Fresenius SE & Co High-end Generic Drug Product Offerings
Table 64. Fresenius SE & Co High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Fresenius SE & Co Key News & Latest Developments
Table 66. Lupin Limited Company Summary
Table 67. Lupin Limited High-end Generic Drug Product Offerings
Table 68. Lupin Limited High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Lupin Limited Key News & Latest Developments
Table 70. Endo Pharmaceuticals Inc Company Summary
Table 71. Endo Pharmaceuticals Inc High-end Generic Drug Product Offerings
Table 72. Endo Pharmaceuticals Inc High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 73. Endo Pharmaceuticals Inc Key News & Latest Developments
Table 74. Aurobindo Pharma Limited Company Summary
Table 75. Aurobindo Pharma Limited High-end Generic Drug Product Offerings
Table 76. Aurobindo Pharma Limited High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Aurobindo Pharma Limited Key News & Latest Developments
Table 78. Warner (India) Pharma Private Limited Company Summary
Table 79. Warner (India) Pharma Private Limited High-end Generic Drug Product Offerings
Table 80. Warner (India) Pharma Private Limited High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 81. Warner (India) Pharma Private Limited Key News & Latest Developments
Table 82. Shijiazhuang Pharma Group Company Summary
Table 83. Shijiazhuang Pharma Group High-end Generic Drug Product Offerings
Table 84. Shijiazhuang Pharma Group High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 85. Shijiazhuang Pharma Group Key News & Latest Developments
Table 86. Fosun Pharma Company Summary
Table 87. Fosun Pharma High-end Generic Drug Product Offerings
Table 88. Fosun Pharma High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 89. Fosun Pharma Key News & Latest Developments
Table 90. Yangtze River Pharmaceutical Group Company Summary
Table 91. Yangtze River Pharmaceutical Group High-end Generic Drug Product Offerings
Table 92. Yangtze River Pharmaceutical Group High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 93. Yangtze River Pharmaceutical Group Key News & Latest Developments
Table 94. Sichuan KELUN PHARMACEUTICAL Co., Ltd. Company Summary
Table 95. Sichuan KELUN PHARMACEUTICAL Co., Ltd. High-end Generic Drug Product Offerings
Table 96. Sichuan KELUN PHARMACEUTICAL Co., Ltd. High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 97. Sichuan KELUN PHARMACEUTICAL Co., Ltd. Key News & Latest Developments
Table 98. Nantong Beite Pharmaceutical Machinery Co.,Ltd Company Summary
Table 99. Nantong Beite Pharmaceutical Machinery Co.,Ltd High-end Generic Drug Product Offerings
Table 100. Nantong Beite Pharmaceutical Machinery Co.,Ltd High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 101. Nantong Beite Pharmaceutical Machinery Co.,Ltd Key News & Latest Developments
Table 102. CR Pharmaceutical Group Company Summary
Table 103. CR Pharmaceutical Group High-end Generic Drug Product Offerings
Table 104. CR Pharmaceutical Group High-end Generic Drug Revenue (US$, Mn) & (2018-2023)
Table 105. CR Pharmaceutical Group Key News & Latest Developments
List of Figures
Figure 1. High-end Generic Drug Segment by Type in 2022
Figure 2. High-end Generic Drug Segment by Application in 2022
Figure 3. Global High-end Generic Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global High-end Generic Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global High-end Generic Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by High-end Generic Drug Revenue in 2022
Figure 8. By Type - Global High-end Generic Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global High-end Generic Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global High-end Generic Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global High-end Generic Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global High-end Generic Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global High-end Generic Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global High-end Generic Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America High-end Generic Drug Revenue Market Share, 2018-2029
Figure 16. US High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe High-end Generic Drug Revenue Market Share, 2018-2029
Figure 20. Germany High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia High-end Generic Drug Revenue Market Share, 2018-2029
Figure 28. China High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America High-end Generic Drug Revenue Market Share, 2018-2029
Figure 34. Brazil High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa High-end Generic Drug Revenue Market Share, 2018-2029
Figure 37. Turkey High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE High-end Generic Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Viatris High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Teva High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Organon High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sun Pharma High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bausch Health High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Mylan NV High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis AG High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Pfizer Inc High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Fresenius SE & Co High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Lupin Limited High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Endo Pharmaceuticals Inc High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Aurobindo Pharma Limited High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Warner (India) Pharma Private Limited High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Shijiazhuang Pharma Group High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Fosun Pharma High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Yangtze River Pharmaceutical Group High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Sichuan KELUN PHARMACEUTICAL Co., Ltd. High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Nantong Beite Pharmaceutical Machinery Co.,Ltd High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. CR Pharmaceutical Group High-end Generic Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
• 日本語訳：世界のハイエンド・ジェネリック医薬品市場予測2023-2029：処方薬、非処方薬
• レポートコード：MRC2312MG03304 ▷ お問い合わせ（見積依頼・ご注文・質問）